SARSCOV-2 BILAN OG’RIGAN BEMORLARDA KOAGULYATSION GEMOSTAZNI SHIKASTLANISHINI LABORATORIYAVIY KO’RSATGICHLARINI BAXOLASH

Universal International Scientific Journal

2025, 2(5)

166

Olimjonov Jahongir Tolibjon o’g’li., Djo’rabayev Tolibjon Komildjanovich

Namangan davlat unversiteti

Uzbekistan

jahongir.olimjanov2193@gmail.com

.,

tolibjondjurabaev@gmail.com

Annotatsiya.

Ish maqsadi: SARSCoV-2 bilan og’rigan bemorlarda koagulyatsion gemostaz

ko’rsatgichlarini baxolash va ikkilamchi kasaligi bor bemorlarda giperkoagulyatsiyani rivojlanishini va

SARSCoV-2 bilan og’rigan bemorlarda tomir ichi trombozi rivojlanishi haf omilarini erta laboratoriya

tashxisi. Tadqiqot materiali SARSCoV-2 bilan og’rigan 80 ta bemor olindi.

Kalit so‘zlar:

SARSCoV-2, Koagulyatsion-gemostaz, D-dimer.

Аннотация:

Оценка показателей коагуляционного гемостаза у пациентов с SARSCoV-2 и

выявление ранней лабораторной диагностики развития гиперкоагуляции у пациентов с вторичными

заболеваниями и факторов риска развития внутрисосудистых тромбозов у пациентов с SARSCoV-

2. Материал исследования был получен от 80 пациентов, инфицированных SARSCoV-2.

Ключевые слова:

SARSCoV-2, коагуляция-гемостаз, D-димер.

Abstract:

To evaluate the indicators of coagulation hemostasis in patients with SARSCoV-2 and the

early laboratory diagnosis of the development of hypercoagulability in patients with secondary disease and

the development of intravascular thrombosis in patients with SARSCoV-2. The study material was obtained

from 80 patients with SARSCoV-2.

Keywords:

SARSCoV-2, Coagulation-hemostasis, D-dimer.

UNIVERSAL XALQARO ILMIY

JURNAL

Jurnalning bosh sahifasi:

https://universaljurnal.uz

SARSCOV-2 BILAN OG’RIGAN BEMORLARDA KOAGULYATSION GEMOSTAZNI

SHIKASTLANISHINI LABORATORIYAVIY KO’RSATGICHLARINI BAXOLASH

Universal International Scientific

Journal

e-ISSN:

3060-4540 (online)

Year: 2025 Issue: 2 Volume: 5

Published: 16.05.2025

https://universaljurnal.uz

International indexes

Universal International Scientific Journal

2025, 2(5)

16

7

Language:

Uzbek

Citation:

Olimjonov , J., & Djo’rabayev , T. (2025). ASSESSMENT OF LABORATORY

INDICATORS OF COAGULATION HEMOSTASIS DISORDERS IN PATIENTS WITH SARSCOV-2.

Universal

International

Scientific

Journal,

2(5),

166–169.

Retrieved

from

https://universaljurnal.uz/index.php/jurnal/article/view/1988

Copyright © 2025 by author(s) and Scientific Research Publishing Inc. This work is licensed under

the

Creative

Commons

Attribution

International

License

(CC

BY

4.0).

http://creativecommons.org/licenses/by/4.0/

Dolzarbligi:

SARSCoV-2 butun dunyo

bo'ylab tez tarqalgan, og'ir asoratlar bilan
kechadigan, yangi, infeksion kasallikdir.
Ba'zi ma’lumotlar shuni ko'rsatadiki,
yuqtirgan odamlarning 80% da yengil va
o’rta og’ir klinik kechishi kuzatilib, jiddiy
tibbiy yordamga va statsionar davoga muxtoj
bo'lmaydi [1]

SARSCoV-2- bitta zanjirli RNK virusi

va koronaviruslar oilasiga tegishli. Virus
hujayralarga hujayra yuzasida joylashgan
angiotensinni o'zgartiradigan ferment 2
(ACE-2) retseptorlari orqali kiradi [2]. ACE-
2 retseptorlari nafas olish yo'llari, buyraklar,
qizilo'ngach, siydik yo’lari, qovuq, ichak,
yurak, markaziy asab tizimi hujayralarida
mavjud. Biroq asosiy nishon hujayralari II
turdagi alveolootsitlar [3]

Nafas olish buzilishi kasallikning

asosiy

xususiyati

bo'lsada,

dastlabki

tadqiqotlar shuni ko'rsatadiki, aylanma D-
dimer darajasining ko'tarilishi o'lim xafini
oshiradi.[4.5]

COVID-19 bilan og’rigan bemorlarda

aniq koagulyatsiya buzilishi aniqlandi.
Ushbu gipotezani tasdiqlash uchun Covid-19
bemorlarini autopsiya tekshiruvlari mayda
tomirlar

va

kapilyarlar

ichida

fibrin

trombining mavjudligini ko’rsatdi [6].

Tadqiqot

maqsadi

:

SARSCoV-2

og’rigan

bemorlarda

koagulyatsion

gemostazni

shikaslanishini

laboratoriya

tashxisi.

Material va metodlar:

Tadqiqot

obʼekti sifatida 2 Zangiota yuqumli
kasalliklar shifoxonasida davolangan Covid-
19 bilan og’rigan 80 ta bemorlar olindi. 1-
guruhga 25 (31,25%) ikkilamchi kasligi
bo’lmagan SARSCoV-2 bilan og’rigan
bemorlar, 2-guruhga 30 (37,5%) ta Covid-19
bilan og’rigan, arterial gipertenzensiyasi bor
bemorlar. 3-guruhga 25 (31.25%) Qandli
diabetti bor SARSCoV-2 bilan og’rigan
bemorlar. Nazorat guruhiga yoshi va jinsiga
mos ravishda 15 nafar sog’lom odamlar
olindi.

Tekshirish usullari:

. APTT, AT, D-

dimer, Fib, PT, PT-act, TT; tekshiruv Mindray
C2000-2 koagulometrida “Human” Reagentini
qo’langan holda o’tqazildi.

Natijalar.

1-guruh

bemorlari

va

nazorat guruhi solishtirilganda, AT (91.24%
va N-98.82%; p <0.001);PT (12.80 sek va N-
12.08 sek; <0.001);va TT (20.25 sek va N-
18.34 sek; <0.01);ikki guruh o'rtasida normal
ko’rsatgichlarni ko’rsatdi.

APTT (32.30 sek va N-28.65 sek ;

<0.01); D-dimer (0.8 va N-0,26 mkg/ml; p
<0,001); FIB 4.30 g/L va 2.90 g/L; <0.001)
bemorlarda nazorat guruhiga qaraganda

yuqori (1-jadval).

Universal International Scientific Journal

2025, 2(5)

168

2-guruh bemorlarida nazorat guruhiga

qaraganda APTT (36.45 sek va N-28.65 sek;
<0,05); PT (14.12 sek va N-12.08 sek;
<0.001); TT (25.20 sek va N-18.34 sek;
<0.001); D-dimer (1.5 mkg/ml va N-
0.26mkg/ml; <0.05), Fib (7.12 g/L va N-2.90
g/L; <0.05) nazorat guruhiga qaraganda
yuqori.

AT (70.30 % va N-98.82%; <0.001)

nazorat guruhiga qaraganda kamaygan (1-
jadval).

3-guruh bemorlarida nazorat guruhiga

qaraganda APTT (45.25 sek va N-28.65 sek;
<0,05);PT (17.20 sek va N-12.08 sek;
<0.001); TT (30.45 sek va N-18.34 sek;
<0.001);

D-dimer

(2.4

mkg/ml

va

0.26mkg/ml; <0.05), Fib (9.40 g/L va 2.90
g/L; <0.05) nazorat guruhiga qaraganda
sezilarli ko’paygan. (1-jadval).

AT (60.35% va N-98.82%; <0.001)

nazorat guruhiga qaraganda kamaygan. (1-
jadval).

Jadval-1

Koagulogramma

Parametrlari.

SARS-CoV-

2. 1-guruh

(n = 25)

SARS-CoV-

2. 2-guruh

(n = 30)

SARS-CoV-

2. 3-guruh

(n = 25)

Nazorat

guruhi

(n = 15)

APTT, s

32.30 ± 2.3

36.45 ± 1.25

45.25 ± 1.3

28.65 ± 3.03

AT, %

91.24 ± 2.4

70.30 ± 4.5

60.35 ± 3.4

98.82 ± 3.91

D-dimer, mkg/ml

0.8± 0.12

1.5 ± 0.28

2.4 ± 0.5

0.26 ± 0.18

FIB, g/L

4.30 ± 1.10

7.12 ± 1.35

9.40 ± 2.20

2.90 ± 0.53

PT, s

12.80 ± 2.3

14.12 ± 1.54

17.20 ± 2.25

12.08 ± 2.28

TT, s

20.25 ± 1.50

25.20 ± 1.65

30.45 ± 0.80

18.34 ± 0.92

Umuman olganda bizning natijalar ham

oldingi tekshirilgan natijalarga mos keladi,
qon ivish jarayoni organizimni himoya

funksiyasi

bajaradi, shunday
bo’lsada COVID-
19 bilan og’rigan

bemorlarda gemostaz tizimi ikkilamchi
kasaligi bor bemorlarda buzilish xafi yuqori
bo’ladi.

COVID-19 kasallarida qon ivishi tizimi

ikkilamichi kasaligi bor bemorlarda nazorat
guruhi

bilan

solishtirilganda

D-dimer

ko’rsatgichlari yuqoriligi aniqlandi, AT 3 esa
sezilarli kamaygan. Covid-19 bilan og’rigan
bemorlarda D-dimer, ko’rsatgichini oshishi

0

20

40

60

80

100

120

APTT

AT

D-dimer

Fib

Pt

TT

Koagulogramma

4-guruh

3-guruh

2-guruh

1-guruh

Universal International Scientific Journal

2025, 2(5)

16

9

va AT 3 kamyishi tomir ichi tromb
rivojlanish hafini oshiradi shu maqsadda D-
dimer, AT 3 ko’rsatgichlarini nazorat qilish
uchun labororiya tekshiruvi o’tkazish muhim
ahamyatga ega.

Xulosa:

1.Covid-19 bilan og’rigan bemorlarda

koagulogramma

tekshiruvlari

shuni

ko’rsatdiki hamroh kasaligi bor bemorlarda
koagulopatiya yuzaga kelish hafi yuqori
bo’ldi.

2. Ikkilamchi kasaligi bor bemorlarda

tomir ichi trombozi yuzaga kelishi xafini

oldini olish uchun D-dimer va AT 3
tekshiruvlari muhim ahamyatga ega.

3. Covid-19 bor bemorlarda D-dimer va

AT 3 har 2 kunda bir tekshirib turish
kerakligini, davolash muolajasini qaytartibda
ketayotganligini kuzatish uchun muhimdir
chunki

Covid-19

og’ir

shaklini

o’tqazayotgan

bemorlarda

D-dimer

darajasini yuqoriligi tomir ichi trombini
yuzaga kelishini baholaydi shunga ko’ra
antikoagulyat terapiya muolajalarini amalga
oshirish kerak.

Foydalanilgan adabiyotlar ro‘yhati

1. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan

Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19)
outbreak — an update on the status. // Mil. Med. Res. 2020; 13 (March (1)): 11.

2. Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment

of COVID-19. Int. J. Antimicrob. Agents. 2020;

3. Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress

syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA
Intern. Med. 2020; 180 (7): 934. DOI: 10.1001/ jamainternmed.2020.0994.

4. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical

Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18): 1708-1720.

5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients

with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229): 1054-
1062.

6. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and

cardiac pathology in African American patients with COVID-19: an autopsy series from New
Orleans [published online ahead of print 27 May 2020]. Lancet Respir Med. doi:10.1016/S2213-
2600(20)30243-5.